Translate page

Presentations from the 23rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?

 
EHA 2018 Apperley


Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

  • Patient case history 2013 - 2017
  • ELN and NCCN definitions of response and failure
  • Outcome of 'real-life' 1st line imatinib by Sokol
  • Importance of ACA
  • ABL KD mutation sensitivity
  • CCyR rates for sequential use of NIL and DAS after IM failure
  • 3rd line therapy with Bosutinib
  • Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
  • SCT for CML: the EBMT score

We are very grateful for the support of Brandcast media to produce these webstreams.

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Nicolini


Does IFN-α improve outcome of CML in the TKI era?
Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

  • LSC persistence on TKI
  • IFN-α anti-tumorigenic activities
  • IFN-α alone and CML: last clinical data
  • What do we know nowadays about the combination of IFN-α and TKI?
  • IFN-α alone as maintenance therapy?
  • Conclusions

 We are very grateful for the support of Brandcast media to produce these webstreams.

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Réa


TFR - a new treatment goal of CP-CML patients?
Dr Delphine Réa, Centre-Hospitalo-Universitaire Saint-Louis, Paris, France 

  • Lessons from clinical trials: TKI discontinuation in CP-CML is feasible
  • Deep-molecular responses: definitions
  • Clinical practice: patient case
  • Deep-molecular responses during 1st line TKI treatment
  • TKI discontinuation in CP-CML: transition from trials to standard practice
  • TKI withdrawal syndrome during the treatment-free phase
  • Recommendations for standard practice: definitions and management of relapses
  • Conclusion 1: Evolving treatment goals
  • Conclusion 2: TKI discontinuation in standard practice

We are very grateful for the support of Brandcast media to produce these webstreams.

 -- Virtual Education Program: 2017 Edition

 

Presentations from a CML Opinion Leader Meeting

We are pleased to make available a new series of presentations from the COLT Meeting 2017, a CML Opinion Leader Training that took place in Adelaide (Australia). Modules currently featured include; frontline CML, TKI resistance/failure, future directions for CML, CML related topics and the CML frontier - all presented by leaders in the field. 

Collage COLT 2017 Session 5

Prof. Timothy Hughes     Dr Agnes Yong

 

 

 
Session 5: The CML frontier
  • Making TFR mainstream 
    (Prof. Timothy Hughes)
  • The immunology of CML and immunomodulation
    (Dr Agnes Yong)

 

 

             

Naranie                       

       Dr Naranie Shanmuganathan

                        

 

 Session 4: CML related topics

  • Managing TKI toxicities 
    (Dr Naranie Shanmuganathan)

 

 

Collage VEP Ross White

  Dr David Ross     Dr Deborah White

           

 

 

 Session 3: Future directions for CML

  • TFR trial update 
    (Dr David Ross)
  • Biomarkers and response prediction 
    in CML
    (Dr Deborah White)